Company intelligence / Profile preview

Neurofix Pharma

Ownership: Private
Development stage: Phase 2

Overview

Successfully concluded Phase IIA clinical trial of drug NFX88 for treating neuropathic pain in patients with spinal cord injury, confirming excellent safety profile and preliminary efficacy[1][2]

Therapeutic areas: Neurology
Modalities: Lipid therapies
Industry: Biotech

Drug pipeline

4 assets

AEVI-001

Phase 2

Indications: ADHD

3 more assets in the full pipeline.

Partnerships

Development agreement with Laminar[3]

Beyond the preview

Go deeper on Neurofix Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurofix Pharma.